Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Olmesartan medoxomil/amlodipine/hydrochlorothiazide - Daiichi Sankyo

Drug Profile

Olmesartan medoxomil/amlodipine/hydrochlorothiazide - Daiichi Sankyo

Alternative Names: CS-8635; Sevikar HCT; Sevikar Plus; Tribenzor

Latest Information Update: 05 Nov 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Daiichi Sankyo Company
  • Developer Daewoong Pharmaceutical; Daiichi Sankyo Company
  • Class Antihypertensives; Benzothiadiazines; Dihydropyridines; Imidazoles; Small molecules; Tetrazoles
  • Mechanism of Action Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Thiazide diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Marketed Hypertension

Most Recent Events

  • 18 Jan 2022 Olmesartan medoxomil/amlodipine/hydrochlorothiazide licensed to Cosette Pharmaceuticals in USA
  • 10 Jan 2019 Chemical structure information added
  • 31 Dec 2018 Sungkyunkwan University School of Medicine and Daiichi Sankyo completes the phase III trial in Hypertension in South Korea (PO) (ISRCTN51756760)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top